INTRODUCTION
============

Breast cancer is the most frequently diagnosed cancer and cancer-related death amongst women. Annually, more than two million breast cancer cases are reported worldwide^\[[@B1]\]^. Despite the conventional therapeutic modalities for breast cancer treatment, these therapies have been suggested to be rather ineffective^\[[@B2]\]^.

New studies have shown that immunotherapy can be an effective and alternative choice in treating breast cancer^\[[@B3]\]^. Immunotherapy consists of anti-cancer antibody, cancer vaccine, and T-cell receptor engineering^\[[@B2]\]^. PLAC1 is a cancer/testis antigen with a significant role in cancer progression and invasion^\[[@B4]\]^. Cancer/testis antigens are specific antigens expressed in germ-line cells like testis, fetal ovary, and placenta. These antigens are also expressed in some cancer cells, but rarely found in normal tissues^\[[@B5]\]^. Studies have revealed that PLAC1 expression in normal cells is not adequate to be measured, while its expression in cancer cells is measurable^\[[@B5],[@B6]\]^. Recently, it has been displayed that PLAC1 plays a critical role in tumor invasion and metastasis through Furin/NICD/PTEN/AKT axis^\[[@B7]\]^. PLAC1 is a type II membrane bound protein, which its 5-22 amino acids form a transmembrane helix, and has a large extracellular domain consisting of 23-212 amino acids. A truncated zona pellucida domain in the extracellular part of PLAC1 is made of amino acids 29-119^\[[@B8]\]^. New research on PLAC1 has indicated that it is well expressed in a versatile cancer cases, specifically in breast cancer, but not expressed in normal tissues, except testis^\[[@B9]\]^. Therefore, PLAC1 could be a specific target for breast cancer immunotherapy.

Vaccines need an adjuvant to be more effective^\[[@B10]\]^. Adjuvants induce TLR, which results in helper T-cell activation. Bacterial flagellin is one of the most important protein adjuvants that induces TLR5 receptors^\[[@B11]\]^. FliC protein is the main component of flagellin and encoded by *flic* gene^\[[@B12]\]^. *Salmonella enterica* serovar typhimurium FliC, as an efficient adjuvant, is widely used in vaccine research^\[[@B13]\]^. FliC is made of four domains, including D0, D1, D2, and D3. D1 is responsible for TLR5 binding and dimerization of TLR5s and triggers the downstream signaling and stimulates cells to secrete proinflammatory cytokines such as TNF-α^\[[@B14]\]^. Flagellin is a TLR5 binding ligand and starts downstream signaling through MyD88 pathway, which activates innate immunity. It has been shown that the innate immune system motivation results in cytokines secretion and dendritic cells activation^\[[@B15]\]^.

The aim of this study was to design a fusion protein construct, as an effective vaccine, consisting of PLAC1 (as a specific antigen) and *Salmonella enterica*fliC (as a bacterial adjuvant) that can stimulate humoral and cellular immune responses against breast cancer. This construct was evaluated using bioinformatics online web servers.

MATERIALS AND METHODS
=====================

**Construct design**

In this study, the amino acid sequences of PLAC1 and fliC were extracted from Uniprot database (https://www.uniprot.org/[)]{.ul} in FASTA format (Uniprot id: Q9HBJ0). Amino acids 23-212 of PLAC1 were considered for the construct design, and residues 1-22 were neglected because they are located in plasma membrane and cytosol, and the humoral immunity does not have access to them. A flexible linker (GSGGSGGSGGSG) was located between PLAC1 antigen and fliC adjuvant. Our final construct was PLAC1 (23-212)-linker (GSGGSGGSGGSG)-fliC.

**Prediction of physicochemical properties and** **secondary structure**

[To predict]{.ul}different physicochemical features, such as instability index, isoelectric point, aliphatic index, grand average of hydropathicity, and molecular weight for PLAC1-fliC, we utilized ProtParam server (https://web.expasy.org/protparam/[)]{.ul}^\[[@B16]\]^. Secondary structure of PLAC1, fliC, and PLAC1-fliC were predicted using GOR V server (https://abs.cit.nih.gov/ gor/[)]{.ul} and were compared together^\[[@B17]\]^.

**Tertiary structure prediction and refinement**

Phyre2 server (http://www.sbg.bio.ic.ac.uk/\~phyre2/ html/page.cgi?id=index) was employed to predict the 3D structure of the construct based on homology modeling method^\[[@B18]\]^. The model was refined using GalaxyRefine server (http://galaxy. seoklab.org/cgi-bin/submit.cgi?type=REFINE)^\[[@B19]\]^, and the best refined model was selected and submitted for next steps.

**Validation of tertiary structure**

For the validation of the model, the following servers were used: RAMPAGE (http://servicesn.mbi.ucla.edu/ PROCHECK/[)]{.ul}, ProSA-web (https://prosa.services. came.sbg.ac.at/prosa.php), and PROCHECK (http:// servicesn.mbi.ucla.edu/PROCHECK/[)]{.ul}. RAMPAGE server has ability to check stereochemical qualities of the models peptide bonds and shows the number of residues in favored, allowed and outer areas in a Ramachandran plot. ProSA-web has a diagnostic method that is able to analyze protein structures based on all the available protein structures^\[20\]^. PROCHECK server was employed for evaluating the stereochemical quality of the PLAC1-fliC^\[[@B21]\]^. The results of all the three servers were compared before and after 3D structure model refinement.

**Antigenicity** **and allergenicity prediction**

VaxiJen server (http://www.ddg-pharmfac.net/ vaxijen/VaxiJen/ VaxiJen.html[)]{.ul} was used for the prediction of protective antigens and subunit vaccines. According to the physicochemical properties of proteins, this server classifies antigens without referral to sequence alignment. The accuracy of the server based on the origin of the protein (bacterial, viral, and tumor protein datasets) varies between 70 and 89%^\[[@B22]\]^. Antigenicity of the construct was rechecked by ANTIGENpro (<http://scratch.proteomics.ics.uci.edu/>), which is based on pathogen independent, sequence-based, alignment-free analysis and uses antigenicity microarray data for predicting the protein antigenicity. SDAP (http://fermi.utmb.edu/SDAP/sdap_man.html[) and]{.ul}AllergenFP (http://www.ddgpharmfac.net/ AllergenFP/) databases were employed for allergenicity prediction of the fusion protein. SDAP is the structural database of allergenic proteins, while AllergenFP online bioinformatics tool is based on descriptor fingerprint^\[[@B23]\]^.

![Amino acid composition of PLAC1-fliC construct. Red shows PLAC1, black indicates a flexible linker, and green shows fliC](ibj-24-173-g001){#F1}

**MHC-I and MHC-II binding epitope prediction**

NetMHC 4.0 Server (http://www.cbs.dtu.dk/services/ NetMHC/) and NetMHCII 2.3 Server (http://www.cbs. dtu.dk/services/NetMHCII/[)]{.ul}were applied to predict MHC-I binding epitopes (based on an artificial neural networks method) and MHC-II binding epitopes, respectively^\[[@B24],[@B25]\]^.

**B cell and CTL epitopes prediction**

B-cell epitopes, both continuous and discontinuous, were predicted using ElliPro server (http://tools. iedb.org/ellipro/)^\[[@B26]\]^. CTLPred server (http://crdd.osdd. net/raghava/ctlpred/) was utilized for the prediction of CTL epitopes based on the direct method. This method uses data on T-cells epitopes templates instead of MHC-binding peptides. CTLpred method is based on techniques such as artificial neural network and support vector^\[[@B27]\]^.

RESULTS
=======

**Physicochemical properties**

The fusion construct was designed ([Fig. 1](#F1){ref-type="fig"}). The predicted molecular weight and isoelectric point for our fusion protein were 73642.54 Da and 5.17, respectively. Total numbers of negatively and positively charged amino acids of this protein were 73 and 55; thus, its final charge was -18, and it totally had a negative charge. Instability index for PLAC1-fliC protein was 32.87, which was considered as the stable protein; the instability index under 40 means stability. Aliphatic index and grand average of hydropathicity of our fusion protein were 76.85 and -0.380, respectively.

**Secondary structure**

Our findings showed that PLAC1-fliC had 29.31% alpha helix, 21.98% extended strand, and 48.71% random coil. Comparison between PLAC1, fliC, and PLAC1-fliC is shown in [Table 1](#T1){ref-type="table"}, and the secondary structure pattern of PLAC1-fliC is indicated in [Figure 2](#F2){ref-type="fig"}.

**Homology model building, refinement, and validation**

The PLAC1-fliC protein model was built using Phyre2 based on Hidden Markov Model. [Figure 3](#F3){ref-type="fig"} depicts fusion protein predicted tertiary structure. This model was refined using GalaxyRefine server, and five refined models were built, and the best one was chosen. ProSA Z-scores for PLAC1-fliC 3D model after and before refinement were -8.38 and -9.21, respectively ([Fig. 4](#F4){ref-type="fig"}). RAMPAGE results showed that the numbers of residues increased in the favored region after the model refinement. These findings were confirmed by PROCHECK results ([Table 2](#T2){ref-type="table"}).

###### 

Comparison of PLAC1, fliC, and PLAC1-fliC fusion secondary structures

  ------------- --------------------- ------------------------- ---------------------
  **Protein**   **Alpha helix (%)**   **Extended strand (%)**   **Random coil (%)**
  PLAC1         5.26                  36.32                     58.42
  fliC          39.27                 16.19                     44.53
  PLAC1-fliC    29.31                 21.98                     48.71
  ------------- --------------------- ------------------------- ---------------------

![Graphical results of secondary structures comparison. Helix, extended strand, and random coil are indicated by blue, purple and red, respectively](ibj-24-173-g002){#F2}

**Antigenicity and allergenicity**

ANTIGENpro and VaxiJen results revealed that fliC, as an adjuvant, could increase the antigenicity of PLAC1 protein. [Table 3](#T3){ref-type="table"} shows the antigenicity of PLAC1, fliC, linker, and PLAC1-fliC fusion protein. In accordance with AllergenFP server, our findings suggested that PLAC1, fliC, and PLAC1-fliC could not be an allergen for human body. Searching PLAC1, fliC, and PLAC1-fliC sequences in SDAP database showed that these sequences were not allergens, and, therefore, AllergenFP results were confirmed.

**MHCI and MHCII-binding epitopes**

Since 9-mer peptides display more tendency to HLA1, peptides with nine amino acids were chosen. The 9-mer peptides with strong binding preference to HLA-A0201 subtype with their affinity and rank are shown in [Table 4](#T4){ref-type="table"}. To predict MHC-II binding, 15-mer peptides binding to DRB1\_ 0301, DRB1\_ 0401, DRB1\_ 0701, and DRB1\_ 1501 were evaluated. Our finding exhibited that PLAC1-fliC epitopes were strong binders to DRB1\_ 0301 and DRB1\_ 0401 ([Table 5](#T5){ref-type="table"}).

**B cell and** **CTL** **epitopes**

Using ElliPro, B cell specific continuous (linear) and discontinuous (conformational) epitopes were defined. Accordingly, 16 continuous epitopes were identified, and their length was between 6-110 amino acids ([Table 6](#T6){ref-type="table"}). In addition, 4 discontinuous epitopes were predicted with maximum 177 and minimum 15 amino acids in length ([Table 7](#T7){ref-type="table"}). Top 10 CTL peptide epitopes with higher scores predicted by combined approach, artificial neural network/support vector machine, are shown in [Table 8](#T8){ref-type="table"}.

DISCUSSION
==========

According to the global cancer statistics in 2018, breast cancer is the most commonly diagnosed and the leading cause of cancer-related death among women^\[[@B1]\]^. However, there are merely few therapeutic strategies with limited success against breast cancer^\[[@B28]\]^. One new therapeutic strategy against cancer is immunotherapy. Cancer vaccine is one of the most effective immunotherapy treatments, but its design and production is often time-consuming and costly. The new generation of vaccines are based on recombinant protein technology according to their specific design, safety, purity, and feasibility of production^\[[@B29]\]^. Thus, finding and screening the putative vaccine candidate is a prerequisite for its production. In a previous study, Kawada *et al.*^\[[@B30]\]^ vaccinated 13 patients using NY-ESO-1, a cancer-testis antigen. This antigen induces antibody production, as well as CD4 and CD8 T-cell responses. Furthermore, Shim *et al.*^\[[@B31]\]^ showed that cancer-associated peptides, as a cancer/testis antigen, can stimulate CTL. Thanks to the integration of biology and computer sciences, there are many available software and webservers that enable us to design and validate biological processes in a dry lab as *in silico*. Hence, we designed a candidate vaccine as a fusion protein, containing PLAC1, which is expressed highly in several types of tumor tissues, but not in normal ones, except placenta and testis^\[[@B32]\]^. PLAC1 is a suitable candidate for cancer immunotherapy, since it is overexpressed in more than 80% of breast cancers samples, while overexpression of Her2/neu, the target of Herceptin monoclonal antibody, is utmost 25%^\[[@B8],[@B33]\]^. Second part of this fusion protein vaccine is ﬂiC from *Salmonella enterica*, which as an adjuvant molecule might be able to stimulate both humoral and cellular immune responses^\[[@B34]\]^. Third part of this construct is a flexible linker, GSGGSGGSGGSG, which resides between the mentioned parts and contains repeated small or polar amino acids (glycine and serine). Such linkers provide favorable solubility and flexibility and join two domains of fusion protein without changing their structure and function^\[[@B35],[@B36]\]^.

![The 3D structure of PLAC1-fliC defined by Phyre 2.](ibj-24-173-g003){#F3}

![The Z-score plot for the 3D model of PLAC1-fliC before (A) and after (B) refinement. Z-score is shown by a black spot](ibj-24-173-g004){#F4}

The construct structure was analyzed and validated using diﬀerent bioinformatics tools and servers. Based on the results of different physicochemical parameters and structural analysis, PLAC1-fliC is a stable hydrophilic protein with a net negative charge. Its favorite degree of stability enables it to circulate easily and to be processed by antigen-presenting cells because proteins with a very loose conformation are susceptible to tertiary conformational epitope changes and might degrade easily. On the other hand, rigid structures might resist against antigen processing and epitope presentation^\[[@B37]\]^.

Secondary structures of polypeptides play an important role in their ultimate structure and function. Forecasting secondary structure from their amino acids sequences is the prerequisite for proteins 3D structure prediction, as well as for prediction of protein stability. GOR V server was used to predict the secondary structure of PLAC1-fliC. It works according to Garnier-Osguthorpe-Robson method that uses combined mathematical tools, probability methods, and data have been extracted from empirical methods like NMR and crystallography^\[[@B38]\]^. [Table 1](#T1){ref-type="table"} reveals that the percentage of PLAC1-fliC random coil and alpha helix reduced and ioncreased, respectively. Therefore, its structure got more regular in comparison with PLAC1. Indeed, alpha helices are more stable than beta strands and random coils and more firm to conformational changes^\[[@B39]\]^. PLAC1-fliC modeling, refinement and validation were accomplished via different servers. Based on RAMPAGE results, most residues were located in allowed and favorite regions, and even the scores got better after refinement. These results were validated by PROCHECK, as well ([Table 2](#T2){ref-type="table"}). The predicted model of PLAC1-fliC, when compared with the experimental structures, indicated that this model was valid and matched with experimentally determined structures. Appropriate ProSA Z-scores confirms the accuracy of this model ([Fig. 4](#F4){ref-type="fig"})^\[[@B20]\]^.

###### 

Comparison of residues residence in Ramachandran plot before and after model refinement

  **Database**                     **Before refinement**   **After refinement**
  -------------------------------- ----------------------- ----------------------
  RAMPAGE                                                  
  Number of residues in                                    
  Favored region (%)               603 (86.9)              640 (92.2)
  Allowed region (%)               54 (7.8)                33 (4.8)
  Outlier region (%)               37 (5.3)                21 (3.0)
                                                           
  PROCHECK                                                 
  Residues in                                              
  Most favored regions (%)         500 (81.2)              528 (85.7)
  Additional allowed regions (%)   81 (13.1)               63 (10.2)
  Generously allowed regions (%)   23 (3.7)                14 (2.3)
  Disallowed regions (%)           12 (1.9)                11 (1.8)

###### 

Antigenicity predictions of PLAC1, fliC, linker, and PLAC1-fliC

  **Protein**   **ANTIGENpro**   **VaxiJen** ^\*^
  ------------- ---------------- ------------------
  PLAC1         0.947422         0.6587
  fliC          0.923670         0.8246
  linker        0.453669         1.8025
  PLAC1-fliC    0.955086         0.7320

\* Threshold = 0.5

Since the presence of flagella protein domain, as an adjuvant in the construct, might be allergenic for human; it is necessary to evaluate its potential allergenicity. It is important that vaccines could not be an allergen for humans. Allergens provoke hosts immune system and might lead to undesirable allergenic reactions^\[[@B40]\]^. The allergenicity prediction result showed that PLAC1-fliC was not allergen for humans; therefore, it can be administrated safely.

For stimulating immune responses against cancer cells and eventually eradicating them, their specific antigen epitopes have to be presented to immune cells, including B and T lymphocytes. Intrinsic antigens like cancer epitopes are presented to CTL by MHC-I, and extrinsic antigen such as adjuvants are presented to T helper cells by MHC-II molecules. Commonly, MHC-I presents 8-11 amino acids of peptides, while MHC-II presents peptides with 12-25 amino acids in length; they interact with T-cell receptor and eventually lead to cellular immune response^\[[@B41]\]^. The MHC genes are one of the most polymorphic human genes, and their frequency varies among populations, races, and ethnic groups. To predict the presenting potency and binding affinity of PLAC1-fliC in antigen-presenting cells, we selected the MHC-I and MHC-II alleles based on their global and regional relative haplotypes frequency according to scientific reports by investigating their frequency in allele frequency database^\[[@B42]-[@B46]\]^. As [Table 4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} show, immunodominant 9-mer peptide of PLAC1-fliC strongly binds to MHC-I haplotype HLA-A0201, and 15-mer epitope of PLAC1-fliC binds to DRB1\_ 0301 and DRB1\_ 0401 MHC-II haplotypes. These results exhibit that PLAC1-fliC could be presented efficiently to immune cells and could evoke immunity against cancer cells. In addition, circulating antigens like protein-based vaccines could act as B-cell epitope and result in B-cell activation, antibody production, and humoral immunity stimulation. B-cell epitope is an antigenic determinant, recognized by antibodies or B-cell receptors. It can be a peptide, called the linear or continuous epitope, or it can have a 3D structure which is considered as a conformational or discontinuous epitope. B-cell epitopes of an antigen are antibody production stimulators^\[[@B26]\]^. Based on [Tables 6](#T6){ref-type="table"}-[8](#T8){ref-type="table"}, PLAC1-fliC has both linear and conformational epitopes with strong affinity to B and T cells; therefore, it could potentially evoke humoral and cellular immunity.

In conclusion, our investigation regarding probable vaccine for breast cancer reveals that PLAC1-fliC contains suitable structure and stability that could effectively stimulate both cellular and humoral immunity and might be safe to administer. Since our study is a bioinformatics analysis, experimental studies are warranted for validity of our results.

###### 

HLA1-binding peptides based on NetMHC 4.

  **Peptide sequence**   **Position**   **HLA**     **Affinity (nM)**   **Rank (%)**   **Binding level**
  ---------------------- -------------- ----------- ------------------- -------------- -------------------
  FMLNNDVCV              19             HLA-A0201   7.53                0.07           SB
  FMVTVHPFM              12             HLA-A0201   10.81               0.12           SB
  SIDWFMVTV              8              HLA-A0201   26.82               0.40           SB
  VLCSIDWFM              5              HLA-A0201   35.00               0.50           SB

SB, strong binder

###### 

HLA2-binding peptides based on NetMHCII 2.3

  **Peptide sequence**   **Position**   **HLA**     **Affinity (nM)**   **Rank (%)**   **Binding level**
  ---------------------- -------------- ----------- ------------------- -------------- -------------------
  DTTIALDNSTFKASA        1              DRB1_0301   15.5                0.50           SB\*
  ADTTIALDNSTFKAS        2              DRB1_0301   17.0                0.50           SB
  TTIALDNSTFKASAT        3              DRB1_0301   17.3                0.60           SB
  YADTTIALDNSTFKA        4              DRB1_0301   22.0                0.80           SB
  HPFMLNNDVCVHFHE        5              DRB1_0301   22.7                0.80           SB
  PFMLNNDVCVHFHEL        6              DRB1_0301   24.3                0.90           SB
  VHPFMLNNDVCVHFH        7              DRB1_0301   27.2                1.10           SB
  TIALDNSTFKASATG        8              DRB1_0301   33.6                1.40           SB
  FMLNNDVCVHFHELH        9              DRB1_0301   40.2                1.70           SB
  GYADTTIALDNSTFK        10             DRB1_0301   42.3                1.80           SB
  QNRFNSAITNLGNTV        1              DRB1_0401   6.3                 0.01           SB
  VQNRFNSAITNLGNT        2              DRB1_0401   6.6                 0.01           SB
  NRFNSAITNLGNTVN        3              DRB1_0401   7.3                 0.03           SB
  AVQNRFNSAITNLGN        4              DRB1_0401   8.1                 0.04           SB
  RFNSAITNLGNTVNN        5              DRB1_0401   11.7                0.12           SB
  GAVQNRFNSAITNLG        6              DRB1_0401   16.1                0.30           SB
  DSDYATEVSNMSRAQ        7              DRB1_0401   17.7                0.40           SB
  SDYATEVSNMSRAQI        8              DRB1_0401   19.0                0.40           SB
  EDSDYATEVSNMSRA        9              DRB1_0401   19.7                0.50           SB
  IEDSDYATEVSNMSR        10             DRB1_0401   27.9                0.90           SB
  DTTIALDNSTFKASA        11             DRB1_0401   29.5                1.00           SB
  DYATEVSNMSRAQIL        12             DRB1_0401   30.2                1.00           SB
  TTIALDNSTFKASAT        13             DRB1_0401   33.7                1.20           SB
  ADTTIALDNSTFKAS        14             DRB1_0401   33.9                1.20           SB
  VHPFMLNNDVCVHFH        15             DRB1_0401   42.5                1.70           SB
  GHNFKAQPDLAEAAT        16             DRB1_0401   44.9                1.80           SB
  TVHPFMLNNDVCVHF        17             DRB1_0401   45.4                1.90           SB
  RAQILQQAGTSVLAQ        1              DRB1_0101   8.3                 1.90           SB

\*SB strong binder

###### 

Predicted B-cell linear epitopes of PLAC1-fliC

  --------------------------------------------------------------------------------------------------------------
  **No.**   **Start**   **End**   **Peptide**                               **Number of residues**   **Score**
  --------- ----------- --------- ----------------------------------------- ------------------------ -----------
  1         378         487       QQKYKVSDTAATVTGYADTTIALDNSTFKASATGLGG\    110                      0.815
                                  TDQKIDGDLKFDDTTGKYYAKVTVTGGTGKDGYY\                                
                                  EVSVDKTNGEVTLAGGATSPLTGGLPATATEDVKNVQVA                            

  2         76          90        IHYSSKGTPSKFVIP                           15                       0.787

  3         14          51        MVTVHPFMLNNDVCVHFHELHLGLGCPPNHVQPHAYQF    38                       0.778

  4         1           6         QSPMTV                                    6                        0.74

  5         237         261       GLRINSAKDDAAGQAIANRFTANIK                 25                       0.726

  6         173         194       LDISEDWSLHTDDMIGSMGSGG                    22                       0.708

  7         679         696       SVLAQANQVPQNVLSLLR                        18                       0.69

  8         151         168       HTQVPCHQAGAQEAQPLQ                        18                       0.662

  9         513         523       SYTDNNGKTID                               11                       0.654

  10        107         123       SMRVASKSRATAQKDEK                         17                       0.649

  11        298         310       AVQSANSTNSQSD                             13                       0.637

  12        196         222       GGSGGSGMAQVINTNSLSLLTQNNLNK               27                       0.61

  13        138         145       NCDCPPCV                                  8                        0.593

  14        603         615       ATTTENPLQKIDA                             13                       0.588

  15        647         658       NLTSARSRIEDS                              12                       0.585

  16        347         359       TIQVGANDGETID                             13                       0.581
  --------------------------------------------------------------------------------------------------------------

###### 

Predicted B-cell discontinuous epitopes of PLAC1-fliC

  **No.**   **Residues**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   **Number of residues**   **Score**
  --------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------ -----------
  1         :A298, \_:V299, \_:Q300, \_:S301, \_:A302, \_:N303, \_:S304, \_:T305, \_:N306, \_:S307, \_:Q308, \_:D310, \_:V377, \_:Q378, \_:Q379, \_:Y381, \_:K382, \_:V383, \_:S384, \_:D385, \_:T386, \_:A387, \_:A388, \_:T389, \_:V390, \_:T391, \_:G392, \_:Y393, \_:A394, \_:D395, \_:T396, \_:T397, \_:I398, \_:A399, \_:L400, \_:D401, \_:N402, \_:S403, \_:T404, \_:F405, \_:K406, \_:A407, \_:S408, \_:A409, \_:T410, \_:G411, \_:L412, \_:G413, \_:G414, \_:T415, \_:D416, \_:Q417, \_:K418, \_:I419, \_:D420, \_:G421, \_:D422, \_:L423, \_:K424, \_:F425, \_:D426, \_:D427, \_:T428, \_:T429, \_:G430, \_:K431, \_:Y432, \_:Y433, \_:A434, \_:K435, \_:V436, \_:T437, \_:V438, \_:T439, \_:G440, \_:G441, \_:T442, \_:G443, \_:K444, \_:D445, \_:G446, \_:Y447, \_:Y448, \_:E449, \_:V450, \_:S451, \_:V452, \_:D453, \_:K454, \_:T455, \_:N456, \_:G457, \_:E458, \_:V459, \_:T460, \_:L461, \_:A462, \_:G463, \_:G464, \_:A465, \_:T466, \_:S467, \_:P468, \_:L469, \_:T470, \_:G471, \_:G472, \_:L473, \_:P474, \_:A475, \_:T476, \_:A477, \_:T478, \_:E479, \_:D480, \_:V481, \_:K482, \_:N483, \_:V484, \_:Q485, \_:V486, \_:A487, \_:S513, \_:T515, \_:D516, \_:N517, \_:N518, \_:G519, \_:K520, \_:T521, \_:I522, \_:D523, \_:D542                                                                                                                                                                                                                                                                                                                                      133                      0.787
  2         :Q1, \_:S2, \_:P3, \_:M4, \_:T5, \_:V6, \_:M14, \_:V15, \_:T16, \_:V17, \_:H18, \_:P19, \_:F20, \_:M21, \_:L22, \_:N23, \_:N24, \_:D25, \_:V26, \_:C27, \_:V28, \_:H29, \_:F30, \_:H31, \_:E32, \_:L33, \_:H34, \_:L35, \_:G36, \_:L37, \_:G38, \_:C39, \_:P40, \_:P41, \_:N42, \_:H43, \_:V44, \_:Q45, \_:P46, \_:H47, \_:A48, \_:Y49, \_:Q50, \_:F51, \_:V65, \_:S66, \_:Q67, \_:D68, \_:M69, \_:I76, \_:H77, \_:Y78, \_:S79, \_:S80, \_:K81, \_:G82, \_:T83, \_:P84, \_:S85, \_:K86, \_:F87, \_:V88, \_:I89, \_:P90, \_:Q97, \_:K98, \_:S99, \_:T103, \_:C106, \_:S107, \_:M108, \_:R109, \_:V110, \_:A111, \_:S112, \_:K113, \_:S114, \_:R115, \_:A116, \_:T117, \_:A118, \_:Q119, \_:K120, \_:D121, \_:E122, \_:N138, \_:C139, \_:D140, \_:C141, \_:P142, \_:P143, \_:C144, \_:V145, \_:H151, \_:T152, \_:Q153, \_:V154, \_:P155, \_:C156, \_:H157, \_:Q158, \_:A159, \_:G160, \_:A161, \_:Q162, \_:E163, \_:A164, \_:Q165, \_:P166, \_:L167, \_:Q168, \_:L173, \_:D174, \_:I175, \_:S176, \_:E177, \_:D178, \_:W179, \_:S180, \_:L181, \_:H182, \_:T183, \_:D184, \_:D185, \_:M186, \_:I187, \_:G188, \_:S189, \_:M190, \_:G191, \_:S192, \_:G193, \_:G194, \_:S195, \_:G196, \_:G197, \_:S198, \_:G199, \_:G200, \_:S201, \_:G202, \_:M203, \_:A204, \_:Q205, \_:V206, \_:I207, \_:N208, \_:T209, \_:N210, \_:S211, \_:L212, \_:S213, \_:L214, \_:L215, \_:Q217, \_:N218, \_:N219, \_:N221, \_:K222, \_:S679, \_:V680, \_:L681, \_:A682, \_:Q683, \_:A684, \_:N685, \_:Q686, \_:V687, \_:P688, \_:Q689, \_:N690, \_:V691, \_:L692, \_:S693, \_:L694, \_:L695, \_:R696   177                      0.687
  3         \_:G237, \_:L238, \_:R239, \_:I240, \_:N241, \_:S242, \_:A243, \_:K244, \_:D245, \_:D246, \_:A247, \_:A248, \_:G249, \_:Q250, \_:A251, \_:I252, \_:A253, \_:N254, \_:R255, \_:F256, \_:T257, \_:A258, \_:N259, \_:K261, \_:T347, \_:Q349, \_:V350, \_:G351, \_:A352, \_:N353, \_:D354, \_:G355, \_:E356, \_:T357, \_:D359, \_:T644, \_:N647, \_:L648, \_:S650, \_:A651, \_:R652, \_:S653, \_:R654, \_:I655, \_:E656, \_:D657, \_:S658, \_:Y660                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 48                       0.667
  4         \_:G371, \_:L372, \_:L375, \_:A569, \_:A602, \_:A603, \_:T604, \_:T605, \_:T606, \_:E607, \_:N608, \_:P609, \_:L610, \_:Q611, \_:K612                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          15                       0.500

###### 

Predicted CTL epitopes of PLAC1-fliC

  **Peptide rank**   **Start position**   **Sequence**   **Score (ANN/SVM)** ^\*^
  ------------------ -------------------- -------------- --------------------------
  1                  9                    SIDWFMVTV      0.73/1.2411843
  2                  36                   GLGCPPNHV      0.96/0.71105708
  3                  61                   RAKAVSQDM      0.97/0.5147798
  4                  83                   TPSKFVIPV      0.88/0.5965804
  5                  56                   TECGIRAKA      0.85/0.5788711
  6                  87                   FVIPVSCAA      0.94/0.37276101
  7                  70                   VIYSTEIHY      0.82/0.4671223
  8                  22                   LNNDVCVHF      0.57/0.59104808
  9                  119                  QKDEKCYEV      0.95/0.14603929
  10                 6                    VLCSIDWFM      0.46/0.53298459

^\*^Cut-off score: 0.51 (ANN) and 0.36 (SVM); ANN, artificial neural network; SVM, support vector machine
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